Plain-English translation of NCT03761108 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called for people with multiple myeloma — a blood cancer that has become resistant to standard treatments. The medication works by helping your immune system recognize and attack cancer cells. Researchers want to find the safest and most effective dose of this treatment and understand how well it works.
Multiple myeloma can become resistant to current treatments, leaving patients with few options. This medication represents a new approach that harnesses your immune system's natural ability to fight cancer, offering hope for people whose disease no longer responds to conventional therapies.
You likely qualify if…
You likely don't qualify if…
You will receive either as an intravenous infusion (through a vein) or as an injection under the skin, depending on which part of the study you join. The study has two phases: the first phase focuses on finding the right dose and monitoring safety closely, while the second phase tests the medication at specific doses, with some participants also receiving a medication to help prevent side effects. You'll have regular visits for blood tests, physical exams, and scans to track how your cancer responds and monitor for any side effects.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States